Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 12 (3), 29-34

Functional Role of Human interleukin-32 and Nuclear Transcription factor-kB in Patients With Psoriasis and Psoriatic Arthritis

Affiliations

Functional Role of Human interleukin-32 and Nuclear Transcription factor-kB in Patients With Psoriasis and Psoriatic Arthritis

Hani A Al-Shobaili et al. Int J Health Sci (Qassim).

Abstract

Objective: Inflammation and its associated cell signaling events have been well documented in psoriasis and psoriatic arthritis. However, the potential for interleukin (IL)-32 and its associated signaling to provoke an inflammatory response or to contribute in the pathogenesis of psoriasis or psoriatic arthritis are still in early phase. This study determined the role of IL-32 and nuclear transcription factor (NF)-κB in patients with plaque psoriasis and psoriatic arthritis.

Methods: Levels of IL-32 were determined in the plasma samples of patients with plaque psoriasis, psoriatic arthritis, and normal healthy subjects by human IL-32-specific Sandwich enzyme-linked immunosorbent assays. To investigate the role of a transcription factor in these patients, activated NF-κBp65 levels were determined in the peripheral blood mononuclear cells (PBMCs) by highly sensitive NF-κB transcription factor kit.

Results: The levels of IL-32 in the plasma samples of plaque psoriasis or psoriatic arthritis patients were found to be significantly higher as compared with the levels of IL-32 present in the normal human plasma samples (P < 0.01). Levels of activated NF-κB were also found higher in plaque psoriasis or psoriatic arthritic patients as compared with the PBMCs of healthy humans (P < 0.05).

Conclusions: This study shows the role of IL-32 and NF-κB in plaque psoriasis and psoriatic arthritic patients. Results indicate that IL-32 and NF-κB promote inflammation in patients with psoriasis and psoriatic arthritis. Disruption of IL-32 or NF-κB signaling event might provide a novel target for the management of plaque psoriasis and psoriatic arthritis.

Keywords: Interleukin -32; NF-κB; peripheral blood mononuclear cells; psoriasis; psoriatic arthritis.

Figures

Figure 1
Figure 1
Human interleukin-32 in plasma samples of patients with psoriasis and psoriatic arthritis. Production of interleukin-32 protein was determined by sandwich enzyme-linked immunosorbent assay. Results are representative (mean±SEM) of duplicate experiments. *P < 0.05 versus psoriasis or psoriatic arthritis
Figure 2
Figure 2
Activation of NF-κB in peripheral blood mononuclear cells of psoriasis and psoriatic arthritis. Activated NF-κB p65 was determined by highly specific transcription factor ELISA kit (Abcam). The positive control nuclear extract supplied with the kit was used. Data are represented as mean±SD.#P < 0.05 versus PS or PA. NF-κB: Nuclear transcription factor-kappa B, PS: Psoriasis, PA: Psoriatic arthritis, SD: Standard deviation

Similar articles

See all similar articles

Cited by 1 PubMed Central articles

References

    1. Nicholas MN, Gooderham M. Psoriasis, depression, and suicidality. Skin Therapy Lett. 2017;22:1–4. - PubMed
    1. Pitlick M, Flesner J, Ballantini K. Plaque psoriasis: A review of recent guidelines and pharmacologic therapies. Formulary. 2011;46:18–26.
    1. Raychaudhuri SK, Maverakis E, Raychaudhuri SP. Diagnosis and classification of psoriasis. Autoimmun Rev. 2014;13:490–5. - PubMed
    1. Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Physician. 2017;63:278–85. - PMC - PubMed
    1. Papoutsaki M, Costanzo A. Treatment of psoriasis and psoriatic arthritis. Biodrugs. 2013;27:3–12. - PubMed

LinkOut - more resources

Feedback